What Is Liraglutide?
Liraglutide is an acylated analog of human GLP-1, the incretin hormone released by intestinal L-cells after eating. It was developed by Novo Nordisk through deliberate modification of the native GLP-1(7-37) peptide to create a molecule suitable for once-daily dosing. Liraglutide shares 97% amino acid sequence homology with endogenous human GLP-1, with one key substitution (Lys34Arg) and the attachment of a C-16 palmitic acid chain via a glutamic acid spacer at position 26.
These structural modifications give liraglutide three properties that extend its duration of action far beyond the 2-minute half-life of native GLP-1. The fatty acid chain promotes self-association into heptamers at the injection site, slowing absorption. Once in the bloodstream, the palmitate chain binds reversibly to serum albumin (approximately 99% protein binding), creating a circulating reservoir from which free liraglutide is released gradually. Albumin binding also provides partial protection from degradation by dipeptidyl peptidase-4 (DPP-4). The result is a plasma half-life of approximately 13 hours, supporting once-daily dosing.
Liraglutide was first approved by the European Medicines Agency (EMA) in 2009 and by the FDA in January 2010 as Victoza for type 2 diabetes. Following the SCALE clinical trial program, it received a second FDA approval in December 2014 as Saxenda for chronic weight management, making it the first GLP-1 agonist approved for obesity treatment. Since then, generic versions from Teva, Hikma, and other manufacturers have become available following patent expiration in 2024.
Although semaglutide (Ozempic/Wegovy) has largely overtaken liraglutide in clinical preference due to its weekly dosing and greater weight loss efficacy, liraglutide retains several advantages: it has over 15 years of post-marketing safety data, cardiovascular outcome data from the landmark LEADER trial, and pediatric approvals for both diabetes and obesity. For a full head-to-head breakdown, see liraglutide vs semaglutide.
The primary benefits of liraglutide include:
- Clinically meaningful weight loss (6 to 8% average, up to 10%+ in early responders)
- Improved glycemic control and HbA1c reduction in type 2 diabetes
- Demonstrated cardiovascular risk reduction (13% reduction in MACE in the LEADER trial)
- Reduced progression from prediabetes to type 2 diabetes
- Approved for adolescents aged 12+ (obesity) and children aged 10+ (diabetes)
- The longest safety track record of any GLP-1 receptor agonist
How It Works
GLP-1 Receptor Activation
Liraglutide functions as a potent agonist at GLP-1 receptors distributed throughout the pancreas, brain, heart, and gastrointestinal tract. When it binds to receptors on pancreatic beta cells, it stimulates glucose-dependent insulin secretion, meaning insulin is released only when blood glucose is elevated. At the same time, liraglutide suppresses glucagon secretion from alpha cells, reducing hepatic glucose output. This dual pancreatic action improves postprandial and fasting glucose levels without the hypoglycemia risk associated with sulfonylureas or exogenous insulin when used as monotherapy.
Appetite Suppression and Satiety
The weight loss effects of liraglutide are primarily centrally mediated. GLP-1 receptors in the hypothalamic arcuate nucleus and brainstem nucleus tractus solitarius regulate hunger and satiety signals. Liraglutide activates these receptors to reduce appetite, enhance meal-related satiety, and diminish food-reward pathways that drive hedonic eating. Functional neuroimaging studies have shown that liraglutide decreases activation in brain regions associated with food craving when subjects are exposed to food cues.
Gastric Emptying
Liraglutide slows the rate at which food leaves the stomach, contributing to prolonged feelings of fullness and reduced caloric intake per meal. This delayed gastric emptying also blunts post-meal glucose excursions by slowing carbohydrate absorption. However, unlike semaglutide, some evidence suggests that the gastric emptying effects of liraglutide may attenuate with chronic use through tachyphylaxis, while the appetite-suppressing central effects remain sustained.
Cardiovascular Effects
Beyond glucose and weight management, liraglutide exerts direct and indirect cardiovascular benefits. The LEADER trial demonstrated reduced rates of major adverse cardiovascular events (MACE). Proposed mechanisms include reduced inflammation, improved endothelial function, decreased blood pressure, improved lipid profiles, and direct cardioprotective effects via GLP-1 receptors expressed on cardiomyocytes. Weight loss itself also contributes to cardiovascular risk reduction.
Pharmacokinetic Differences From Semaglutide
Both liraglutide and semaglutide work through the same GLP-1 receptor, but their pharmacokinetic profiles differ substantially. Semaglutide has a half-life of approximately 7 days (vs 13 hours for liraglutide), achieved through a larger C-18 fatty diacid chain and an amino acid substitution at position 8 that confers greater DPP-4 resistance. These differences translate to weekly dosing for semaglutide versus daily for liraglutide, and approximately double the weight loss efficacy in head-to-head trials.